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Progress on Red Cells in NA Syndromes: Focus on 
ChAc 
G. Bosman, J. Cluitmans, M. Adjobo-Hermans
Department of Biochemistry, Radboud University Medical Center, Nijmegen, 
The Netherlands
Erythrocyte structure and function depend upon interactions between 
proteins in and associated with the membrane, centered around band 3. 
This protein harbours physiological removal signals and, as a main com-
ponent of the links between the cytoskeleton and the lipid bilayer, plays 
a central role in deformability. Also, as a binding partner of hemoglo-
bin and key glycolysis enzymes, band 3 is the link between the oxygen-
dependent trade-off between ATP production and NADPH-mediated 
protection against oxidative damage. Phosphorylation of band 3 by Lyn 
and Syk kinases is involved in the regulation of these processes. 
The presence of acanthocytes in the blood of patients with chorea-acan-
thocytosis (ChAc) and other NA syndromes provides the rationale for 
attempts to identify the molecular causes and consequences of acantho-
cytosis. The results of this approach indicate that a disturbance of the 
interaction between band 3 and other membrane-cytoskeleton proteins 
is at the center of the causes of the acanthocyte shape. The pathway lead-
ing to this disturbance includes abnormal membrane recruitment of and 
band 3 phosphorylation by Lyn kinase. In most patients, the presence of 
acanthocytes does not have clinical consequences, but various in vitro 
analyses show functional alterations. These alterations are not restricted 
to the acanthocytes in ChAc patients, but are also present in patients 
with other NA and NBIA syndromes. A morphological, functional and 
molecular comparison of the acanthocytes and non-acanthocytes of the 
same patient, and of erythrocytes of various NA and NBIA patients, 
provides additional possibilities to identify the neuropathological 
mechanisms of these disorders. 
Copyright: © 2014 Bosman et al.
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A Vps13-Cdc31 Complex is Directly Required for 
TGN to Late Endosome Vesicular Transport and 
TGN Homotypic Fusion
M. De11, M. Abazeed1, E. J. Brace1, A. N. Oleskie1,2, L. V. Man-
cour1,2, G. Skiniotis1,2, R. S. Fuller
1
1 Department of Biological Chemistry, University of Michigan, Ann Arbor, MI, 
USA, 2 Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA
The yeast Vps13 protein (Vps13p) is the prototype of a family of mol-
ecules that includes human VPS13A, for which loss of function results 
in chorea-acanthocytosis.   The VPS13 gene was first identified for its 
requirement in retrograde transport from the late endosome to the 
Golgi in yeast.  Further genetic, cell biological and biochemical studies 
identified Vps13p as a 357 kDa cytosolic protein implicated in regu-
lating forward transport from the trans Golgi network (TGN) to the 
late endosome and required for a late stage in sporulation (Brickner, 
J.H & Fuller, R.S. 1997. J. Cell Biol. 139:23-36).  Using cell-free fusion 
and transport assays (Brickner et al. 2001. J. Cell Biol. 155:969-978; 
Blanchette, J.M., et al., 2004. J. Biol. Chem. 279:48767-73), we find that 
Vps13p is directly required for TGN homotypic fusion and TGN to 
late endosome vesicular transport.  Extracts from cells with deletions or 
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temperature-sensitive mutations in VPS13 are defective in these fusion 
and transport reactions but are complemented by Vps13p that has been 
purified to near homogeneity from yeast cells.  Soluble, purified Vps13p 
is monomeric and is in complex with the small calmodulin-like protein, 
Cdc31p (yeast centrin).  Cdc31p is required for both cell-free reactions. 
Under reaction conditions, purified Vps13p binds to yeast membranes 
in an ATP-stimulated fashion.  The binding of Vps13p to phosphory-
lated phospholipids and a low resolution electron microscopic structure 
for the protein derived from negative stained (uranyl formate) samples 
will be discussed.  
This work has been supported in part by the Protein Folding Disease 
Fast Forward Initiative, the Advocacy for Neuroacanthocytosis Patients, 
the Endowment for the Basic Sciences at the University of Michigan 
Medical School and NIH RO1 grant GM50915 (RSF). 
Copyright: © 2014 Del et al. 
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Organelle Trafficking is Severely Impaired 
in  Human Neurons Derived from Chorea-
acanthocytosis Patients
H. Glaß1, P. Neumann1, A. Pal1, F. N. Gellerich2, P. Reinhardt3, H. 
R. Schöler3, J. Sterneckert3, A. Storch1,4,5, A. Hermann1,4
1 Division for Neurodegenerative Diseases, Department of Neurology, Dres-
den University of Technology, Dresden, Germany, 2 Department of Neurology, 
Otto von Guericke University Magdeburg, Magdeburg, Germany, 3 Department 
of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedi-
cine, Münster, Germany, 4 DZNE, German Center for Neurodegenerative Dis-
eases, Research Site Dresden, Dresden, Germany, 5 CRTD, Center for Regenera-
tive Therapies Dresden, Dresden University of Technology, Dresden,  Germany
Chorea-acanthocytosis (ChAc) is an autosomal recessive inherited dis-
ease caused by loss-of-function mutations in the VPS13A gene, which 
encodes for chorein protein. The yeast homolog of VPS13A functions 
in vesicle and mitochondrial trafficking. These processes are aberrantly 
regulated in Huntington disease (HD), which is phenotypically very 
similar to ChAc, and suggests that they play an important role in ChAc 
pathogenesis. Therefore, this study focuses on vesicle and mitochon-
dria trafficking. Live imaging of neurons differentiated from induced 
pluripotent stem cells (iPSCs) revealed a decreased lysosome count in 
neurites and reduced motility of mitochondria. Mitochondria were ab-
normally shortened, reminiscent of vesicles. Characterization of patient 
mitochondria by respirometry showed diminished function. It is pos-
sible that the disease progression of HD and ChAc share a common 
underlying mechanism. We are currently investigating genes identified 
as hallmarks of trafficking impairment in HD using qPCR and cytoskel-
eton dynamics via immunocytochemistry and Western blot. 
Copyright: © 2014 Glaß et al.
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EMINA 2 & Friends: Dissecting the Molecular 
Pathophysiology of Chorea-acanthocytosis
A. Hermann
Division for Neurodegenerative Diseases, Department of Neurology, Dresden, 
Germany
Introduction: The European Multidisciplinary Initiative on Neuroac-
anthocytosis (EMINA) has provided detailed clinical characterization 
of the different NA syndromes and collected valuable brain and muscle 
samples of chorea-acanthocytosis (ChAc) patients. ChAc is caused by 
loss-of-function mutations within the gene VPS13A encoding a protein 
of unknown function named chorein. In contrast to other types of neu-
rodegeneration, ChAc shows no abnormal protein inclusions. Within 
the EMINA initiative, we recently found two signaling kinases to be 
involved in ChAc pathogenesis, but the exact pathophysiology remains 
enigmatic.
Overall goal: The overall goal of the EMINA-2 consortium is to dis-
sect the molecular pathophysiology of ChAc caused by mutations in the 
VPS13A gene as a model for NA syndromes to provide novel drug tar-
gets for causal therapies. 
Experimental approach: To use patient material, patient-specific induced 
pluripotent stem (iPS) cell models and animal models (VPS13A-/- mice, 
Drosophila models) of ChAc for studying the effects of VPS13A muta-
tions on intracellular signalling pathways and cytoskeleton formation. 
The EMINA-2 consortium now combines the clinical excellence of 
EMINA including the characterized patient material (blood, brain and 
muscle samples) with basic cell and molecular biology as well as animal 
model research to characterize the molecular events leading to neuro-
degeneration in ChAc. 
Significance: The results will contribute to an understanding of the mo-
lecular pathophysiology of ChAc as a model not only for NA syndromes 
but also for inclusion body-independent neurodegenerative diseases of 
the basal ganglia. This knowledge will help to generate novel causal 
treatment approaches in ChAc and eventually other neurodegenerative 
diseases of the basal ganglia. 
Copyright: © 2014 Hermann
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Case Report: Chorea-acanthocytosis in Iran: Focus 
upon Therapies
S. Karkheiran
Hazarat Rasool Hospital, Iran University of Medical Sciences, Tehran, Iran
Chorea-acanthocytosis (ChAc) is a progressive multisystem neurode-
generative disorder which manifests with several devastating symp-
toms. The complex nature of motor and psychological disorders on one 
hand, and the rarity of the disease on the other, makes physicians and 
researchers unable to reach a definite solution for patients’ sufferings. 
Thus, most of our knowledge in management of this disease is based 
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on small case series and personal experiences. Among the wide range 
of complications in our ChAc patients, oral problems have been very 
challenging to tackle. Dysarthria and dysphagia are two major problems 
that affect most patients. The first one disturbs social relationships, and 
the second one puts patients at high risk of aspiration pneumonia. In 
addition, dysphagia reduces food intake and the ensuing malnutrition 
leaves patients vulnerable to infectious and metabolic disorders. Brux-
ism, not uncommon in ChAc, causes early tooth flattening and decay. 
Lip- and tongue-biting, habitual or dystonic in nature, is not only pain-
ful and deteriorate pre-existing dysphagia, but may result in serious oral 
cavity infection. Finally, drooling is both embarrassing and negatively 
affects speech. Control of these complications with speech therapy, 
mouth guards, anti-cholinergic drugs, and botulinum toxin injection 
into salivary glands and tongue muscles are at best modestly effective. 
Overtreatment worsens speech and swallowing and can be dangerous. 
Frequent visits, gradual dose adjustments, and trials of different treat-
ment methods are necessary factors to achieve acceptable treatment re-
sults. In this presentation, I review and share our experiences in control-
ling the above symptoms in Iranian patients. 
Copyright: © 2014 Karkheiran
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In ChAc Red Cells the Abnormally Activated Lyn 
Affects Ankyrin Multiprotein Complexes and is 
Inhibited by Dasatinib 
F. Lupo1*, E. Tibaldi2*, A. Brunati2, A. Mattè1, A. Siciliano1, A. 
Danek3, R. H Walker4,5, A. Hermann6, L. De Franceschi1
1 Department of Medicine, University of Verona, Verona, Italy, 2 Department of 
Biochemistry, University of Padova, Padova, Italy, 3 Department of Neurology, 
Ludwig-Maximilians-Universität, Munich, Germany, 4 Department of Neurology, 
James J Peters VAMC, Bronx, NY, USA, 5 Mount Sinai School of Medicine, New 
York, NY, USA, 6 Department of Neurology, Dresden University of Technology 
and German Centre for Neurodegenerative Disease (DZNE), Dresden, Ger-
many
Chorea-acanthocytosis (ChAc) is a hereditary neurodegenerative disor-
der, one of the neuroacanthocytosis syndromes (NA). One of the hall-
marks of NA is the presence of circulating acanthocytes, generation of 
which is still under investigation. Recently, we reported increased Tyr-
phosphorylation state of the red blood cell (RBC) membrane proteins 
from ChAc patients, related to abnormal activation of Lyn, an Src fam-
ily kinase (SFKs) (Blood 118; 5652; 2011). In the context of international 
collaboration, we further characterized Lyn signaling pathway in RBC 
from ChAc patients. In ChAc RBCs, we found a weakness of ankyrin-
based multiprotein complex bridging the membrane to the cytoskel-
eton, contributing to the generation of acanthocytes. We then evaluated 
the state of Lyn (active-inactive) in the cytoplasmic fraction from RBC 
of ChAc patients. In ChAc RBCs we found higher levels of phospho-
Lyn-396, corresponding to active Lyn, compared to controls. We then 
evaluated whether classical Lyn inhibitors such as PP2 or Dasatinib, a 
pharmacological Lyn inhibitor, might block Lyn in ChAc RBCs. We 
found that both PP2 (0.1μM) or Dasatinib (0.1 μM) were able to effi-
ciently inhibit Lyn in both ChAc and healthy RBCs. These data suggest 
that in ChAc (i) the abnormal activation of Lyn affects RBC membrane 
mechanical stability weakening both multiprotein complexes bridging 
the membrane to the cytoskeleton; (ii) Lyn activity is inhibited by either 
PP2 or Dasatinib, suggesting Lyn as possible new therapeutic target in 
ChAc.
This work was supported by NA advocacy and Telethon grant GP13005 
and Erare-JTC 2012 (“EMINA2”).
* These two authors contributed equally.
Copyright: © 2014 Lupo et al.
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Analysis of the Effects of the Knock-Down of 
VPS13A in Cell Lines, IPS Cells and Primary 
Cultures
M. Mairhofer1, C. Siegl1, G. Hofstätter1, M. Medjimorec1, A. Kol-
bus1, R. Prohaska2
1 Department of Obstetrics & Gynecology, Medical University of Vienna, Vienna, 
Austria, 2 Max F. Perutz Laboratories, Vienna, Austria
Chorea-acanthocythosis is caused by loss-of-function mutations in the 
VPS13A gene. Functional annotation of VPS13A as a protein involved 
in vesicle transport and lysosomal degradation largely relies on data 
collected in yeast, and the mammalian VPS13A protein remains largely 
uncharacterized. We chose an ecotropic lentiviral knock-down approach 
to study VPS13A function in human cell lines and primary cells. Knock-
down efficacies of different shRNA constructs were analysed by Q-PCR 
and Western blotting, and a reduction below 20% of control VPS13A 
protein levels could be obtained. The most efficient constructs were used 
for knock-down of VPS13A in HeLa cells and iPS cells. In HeLa cells, a 
distinct change in cell morphology was observed in response to VPS13A 
shRNA treatment. Preliminary analysis points towards problems with 
cellular adhesion or migration, which are observed in response to the 
VPS13A knock-down. An in-depth analysis of the phenotype, which fits 
well with previous reports on cytoskeletal abnormalities in VPS13A-
deficient cells, is currently on-going. 
Copyright: © 2014 Mairhofer et al.
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Multiple Functions of Vps13 in Yeast
A.M. Neiman, J.-S. Park, R. Policastro, L. Needleman, L. Mc-
Goldrick
Department of Biochemistry, Stony Brook University, Stony Brook, NY, USA
In yeast, VPS13 plays roles in at least three distinct processes. First, 
VPS13 is required for the trafficking of certain proteins to the vacu-
ole, the yeast equivalent of the lysosome. Second, during the develop-
mental process of sporulation, the VPS13 protein translocates to the 
prospore membrane where it is required for proper morphogenesis of 
this compartment. Third, though usually dispensable for growth, VPS13 
becomes essential for cell viability in genetic backgrounds that lack en-
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doplasmic reticulum/mitochondrial contact sites, suggesting a role for 
VPS13 in mitochondrial homeostasis.
These three phenotypes may reflect distinct functions of VPS13 or they 
may indicate a requirement for the same molecular function in different 
processes at different locations within the cell. In either case, these ac-
tivities are separable genetically. For example, we have identified alleles 
of VPS13 that are defective only in the mitochondrial function as well as 
yeast strains in which the VPS13 mutant displays the mitochondrial and 
sporulation phenotypes, but no trafficking defect.
To better understand the molecular basis for the different roles of 
VPS13, we have begun a structure-function analysis of the protein to 
generate mutants defective in only one aspect of VPS13 function and to 
correlate these phenotypes with changes in protein-protein interactions 
as determined by co-immunoprecipitation and mass spectrometry. In 
addition, to seek insight into what function(s) of VPS13 is relevant to 
chorea-acanthocytosis, cognate mutations corresponding missense al-
leles found in ChAc patients have been introduced into the yeast gene. 
Examination of the effect of these mutations on different VPS13 func-
tions will be described.
Copyright: © 2014 Neiman et al.
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Wide Clinical Phenotype Variability of 
Chorea-acanthocytosis
S. Richelli1, G. Zanusso1, M. Ferlisi2, T. Bovi2, T. Zanoni2, L. De 
Franceschi3, S. Monaco1, S. Ferrari1
1 Neurology Unit, University of Verona, Neurology Unit, Verona, Italy, 2 Neurol-
ogy Unit, Verona, Verona Hospital, Italy, 3 Unit of Internal Medicine, University of 
Verona, Verona, Italy 
Chorea-acanthocytosis (ChAc) is a rare neurodegenerative disease char-
acterized by progressive movement disorder, cognitive and behaviour 
changes, seizures and myopathy. The typical clinical features are limb 
chorea and oral dystonia. Here we report the clinical features of two 
brothers affected with ChAc. Their parents were healthy; however, non-
specific movement disorders were reported in relatives. The 47 year-old 
man was affected by a mild mental retardation and a drug-resistant tem-
poral lobe epilepsy diagnosed since he was 27 years-old. At age 45 years-
old he started to develop choreic movements and dystonia affecting up-
per limbs and oral region. Dysarthria, dysphagia, asymmetric plastic 
rigidity and areflexia at upper and lower limbs were also present. Brain 
MRI showed mild enlargement of ventricular cavities associated with 
focal malacia of the right temporal lobe. A pacemaker was implanted af-
ter a cardiac arrest when he was 45 years-old. In contrast his 53 year-old 
sister started to complain progressive impaired gait with frequent falls 
and slurred speech in her 50s. In few years she developed dysphagia and 
progressive cognitive impairment. A neurological examination disclosed 
the presence of extrapyramidal signs characterised by bradykinesia and 
mask-like expressionless face, without involuntary movements. Brain 
MRI showed bilateral hyperintensities of striatum on T2-weighted 
images. Both patients presented acanthocytes in peripheral blood and 
Western blot analysis showed reduced chorein expression. This report 
highlights the wide intra-familial phenotypic variability of ChAc and 
suggests the consideration of ChAc in the differential diagnosis of juve-
nile parkinsonism and temporal epilepsy with mental retardation.
Copyright: © 2014 Richelli et al.
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Clinical Spectrum and Differential Diagnosis of 
Chorea-acanthocytosis
S.A. Schneider
Department of Neurology, University of Kiel, Kiel, Germany
Chorea-acanthocytosis (ChAc) is an autosomal recessive neurodegenera-
tive disorder due to mutation of the VPS13A (CHAC) gene on chro-
mosome 9q21 encoding chorein. Clinical features include mixed move-
ment disorders (chorea, dystonia with prominent orofacial involvement 
and self-mutilation, tics, parkinsonism, head thrusts), eye movement 
abnormalities suggestive of brain stem involvement, seizures, subcorti-
cal dementia and psychiatric features with impairment of frontal lobe 
function. Myopathy and neuropathy are often present. Neuroimaging 
strongly resembles that in Huntington disease. Blood tests reveal the 
presence of acanthocytosis in the blood smear but this may not always 
be detectable. Elevated creatine kinase is also typical and may be de-
tected before the appearance of neurological symptoms or signs. Protein 
assays or genetic testing can confirm the diagnosis.
ChAc belongs to the group of neuroacanthocytosis syndromes alongside 
with X-linked McLeod syndrome, pantothenate kinase-associated neu-
rodegeneration and Huntington disease-like 2. Furthermore, the differ-
ential diagnosis includes other forms of inherited chorea (Huntington 
disease, other forms of the Huntington-like disorders, other syndromes 
of neurodegeneration with brain iron accumulation [NBIAs], Wilson 
disease and others), but acquired causes should also be considered. 
Copyright: © 2014 Schneider
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Involvement of Vps13 Protein in Protein Trafficking 
and Actin Cytoskeleton in Yeast
T. Zoladek, W. Rzepnikowska, J. Kamińska, M. Grynberg
Institute of Biochemistry and Biophysics Polish Academy of Sciences, Warsaw, 
Poland
Yeast Vps13 was first discovered as a protein involved in the delivery of 
proteins from Golgi apparatus to the vacuole. Null mutant vps13D dis-
played defects in localization of several proteins, such as vacuolar car-
boxypeptidase Y and Golgi apparatus proteins Kex2, Vps10 and Ste13. 
Vps13 is also required for sporulation. However, the molecular function 
of Vps13 is unknown. In humans there are four homologs of yeast Vps13 
and mutations in VPS13A and VPS13B cause the hereditary disorders 
chorea-acanthocytosis and Cohen syndrome, respectively.
We showed that Vps13D mutant has impairment of endocytosis. The 
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null mutant shows delay in internalization of FM4-64 lipophylic dye 
from the plasma membrane to vacuole, and slower growth on cana-
vanine-containing medium, indicating defective endocytosis of Can1 
permease. This mutant also has defects in actin cytoskeleton organiza-
tion: actin patches are not well polarized and abnormal actin clumps 
are present in cells. Dynamic actin cytoskeleton is important for endo-
cytosis but also in selective autophagy pathways. Selective cytoplasm-
to-vacuole (Cvt) pathway was only weakly delayed, as documented by 
Western blot analysis of preApe1 maturation. Nonselective autophagy, 
measured by GFP-Atg8 degradation, was not defective when compared 
with control strain. A Vps13D strain also showed defects in vacuole 
staining by CMAC, a pH-sensitive dye. This mutant was impaired in 
vacuolar localization of Vph1 protein, the subunit of vacuolar ATP-ase, 
and showed slower growth on rich medium at low pH. This may indi-
cate disturbances in pH homeostasis of cells which in turn may affect 
various trafficking steps.
Copyright: © 2014 Zoladek et al.
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The Hematology of McLeod Syndrome – Diagnostic 
and Therapeutic Challenges
B. M. Frey
Blood Transfusion Service, Swiss Red Cross SRC, Schlieren/Zürich, Switzerland
McLeod Syndrome (MLS) is one of the neuroacanthocytosis syndromes, 
characterized by hematological, immunohematological, neuro-psychiat-
ric and other cardinal symptoms. The genetic defect is located on the 
short arm of X chromosome at position Xp21.1 (XK). Currently 27 ab-
errations such as single nucleotide polymorphism, stop codons, inser-
tion/deletion mutation and splice site mutations are recognized. There is 
no well-defined genotype-phenotype correlation of XK mutation. Clini-
cal manifestations are heterogeneous and variable, from asymptomatic 
carrier status to debilitating neuro-psychiatric and cardiodegenerative 
sequelae. Lead diagnostic findings are the pathognomonic aberrations 
of the Kell and Kx blood group antigen systems as well as red cell acan-
thocytosis. In addition, X-chromosomal inheritance with carrier status 
of the mothers of involved males is pivotal for MLS diagnosis. Immuno-
hematological phenotyping of Kell antigens and flow-cytometric assess-
ment of expression of Kell glycoprotein, as well as structured molecular 
characterization of the X-chromosomal defect, constitute the key find-
ings for the diagnosis of MLS. When there are extended deletions of 
Xp21.1, involving centromeric or teleomeric genes such as the CYBB, 
RPGR, OTC or DMD loci, the prototypic hematological findings of 
MLS may be dominated by the phenotypic manifestations of affected 
neighbouring genes of XK (contiguous gene syndrome).
Cellular and subcellular manifestation of XK mutations in hemato-
logical as well as extra-erythropoietic tissues will be reviewed. KEL/
XK-KO mouse models, as well as assessment of transmembrane cation 
transport regulation of MLS red blood cells, may give insights into the 
pathomechanism of MLS manifestation in extra-hematological organs. 
Clinical aspects of MLS patients, in addition to patients with X-linked 
CGD syndrome as examples of contiguous gene syndrome, will be pre-
sented.
Copyright: © 2014 Frey
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News on McLeod Syndrome
H. H. Jung
Department of Neurology, University Hospital Zürich, Zürich, Switzerland
The X-linked McLeod neuroacanthocytosis syndrome (MLS) is charac-
terized by the association of erythrocyte acanthocytosis and progressive 
striatal neurodegeneration. As the autosomal recessive chorea-acantho-
cytosis (ChAc), MLS has a Huntington disease-like phenotype consist-
ing of a hyperkinetic, mostly choreatic, movement disorder, psychiatric 
manifestations and cognitive decline, with a relentlessly progressive 
course over several decades. In addition, MLS patients may have a multi-
system involvement including motor-dominant axonal neuropathy, my-
opathy and cardiomyopathy. McLeod syndrome is exceptionally rare 
with an estimated prevalence of less than 1 to 5 per 1,000,000 inhabit-
ants. In the last years, it has been recognized that MLS has a worldwide 
distribution. MLS is caused by mutations in the XK gene. Although the 
association of the acanthocytic membrane abnormality with selective 
striatal degeneration suggests a common pathogenetic pathway, the pos-
sible mechanisms by which these mutations cause striatal neurodegen-
eration are still a matter of debate and research. The diagnosis of MLS 
involves (often negative) blood smears to detect acanthocytosis, but also 
the determination of serum creatine kinase (CK), which is elevated in 
virtually all MLS patients. Cerebral MRI may demonstrate striatal at-
rophy. Kell and Kx blood group antigens are reduced or absent, thus 
delivering an accurate diagnosis of MLS. Identification of a distinct mu-
tation in the XK gene is confirmatory. The course of McLeod syndrome 
is relentlessly progressive, and there is no curative therapy yet known. 
However, regular cardiologic studies and avoidance of transfusion com-
plications are mandatory. The hyperkinetic movement disorder may be 
treated as in Huntington disease. Other symptoms including psychiatric 
manifestations should be managed in a symptom-oriented manner.
Copyright: © 2014 Jung
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Alterations in Magnesium and Potassium but 
not Sodium Transporters Characterize McLeod 
Syndrome Erythrocytes
J. R. Romero1, A. Markovic1, G. Schorer2, B. M. Frey2, H. H. 
Jung3, R. H. Walker4,5, S. Lee6, A. Rivera1
1 Boston Children’s Hospital, Boston, MA, USA, 2 Blood Transfusion Service, 
Swiss Red Cross SRC, Schlieren/Zürich, Switzerland, 3 Department of Neurol-
ogy, University Hospital Zürich, Zürich, Switzerland, 4 Department of Neurology, 
James J Peters VAMC, Bronx, NY, USA 5 Mount Sinai School of Medicine, New 
York, NY, USA, 6 Membrane Biochemistry Laboratory, Lindsley F. Kimball Re-
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search Institute of the New York Blood Center, New York, NY, USA
We have recently reported a novel alteration in erythrocyte Mg2+ and 
K+ homeostasis in cells from Xk knockout mice, a model of McLeod 
Syndrome (MLS). We now show that in an untreated, asymptomatic 
MLS subject alterations in cellular ion content were associated with 
changes in the activity of 4 major cation transporters in erythrocytes. 
There was an 18% increase in erythrocyte K+ (245.3-298.5 mmol/
Kg Hb), Mg2+ (5.6-7.5 mmol/Kg Hb) and total Ca2+ levels (0.29-0.52 
mmol/Kg Hb) when compared to control cells, suggesting altered ion 
homeostasis. Consistent with this hypothesis, Na+-independent Mg2+ 
permeability (2.0 to 0.6 mmol/1013 cell x h) was significantly reduced, 
implying an abnormality in Mg handling. We also observed that Na/
Mg exchanger (NME) activity was significantly decreased. It has been 
shown that Kell/XK complex are phosphorylated by Casein kinase II 
(CKII). We observed that TBB (4,5,6,7-tetrabromobenzotriazole), a spe-
cific CKII blocker, did not block Big ET-3-stimulated NME activity 
in Xk-mutated erythrocytes, unlike in control cells. These results sug-
gest that alterations in CKII signaling mediate disordered Mg levels in 
MLS. K+ transport mediated by the Gardos channel was increased when 
compared to controls (18 to 26.8 mmol/1013 cell x h). In addition, the 
volume-stimulated and Cl independent K/Cl co-transporter was almost 
two-fold lower when compared to controls. These results are in agree-
ment with a higher K+ content in these cells. In contrast, no differences 
in Na transporter activities were observed. Thus, our results provide 
novel insights into potential mechanisms by which alterations in Kx 
protein lead to abnormalities in erythrocytes transporters, which may 
play critical roles in acanthocytosis development.
Copyright: © 2014 Romero et al.
NBIA – Pantothenate Kinase-Associated 
Neurodegeneration
15  ________________________________________________
Best Practices in the Care and Management of 
People with NBIA: Development of a Guideline for 
PKAN
B. Csányi1, A. Gregory2, P. Hogarth2,3, M. Karakourtis4, M. Fried-
Oken3,5, T. Zagustin6, M. A. Kurian1,7, S. J. Hayflick2,3,5
1 CMGU, Institute of Child Health, London, UK, 2 Department of Molecular & 
Medical Genetics, Health & Science University, Portland, OR, USA, 3 Department 
of Neurology, Oregon Health & Science University, Portland, OR, USA, 4 Depart-
ment of Oral and Maxillofacial Surgery, Westlake Hospital, West Lake Hills, TX, 
USA, 5 Department of Pediatrics, Oregon Health & Science University, Portland, 
OR, USA, 6 Pediatric Rehabilitation Medicine, University of British Columbia, 
Vancouver, BC, Canada, 7 Great Ormond Street Hospital, London, UK
Introduction: Pantothenate kinase-associated neurodegeneration 
(PKAN) is the major genetic subtype of Neurodegeneration with Brain 
Iron Accumulation (NBIA), accounting for 35-50% of cases. The pro-
gressive nature and intractable dystonia in this ultra-rare disorder make 
it a challenge to manage.  To date, there is no comprehensive guideline 
for the diagnosis and management of these patients.
Aims and Methods: We aimed to develop a best practice guideline for 
PKAN, leveraging the wisdom of a small pool of experts, to facilitate 
holistic management. Our team comprised multidiscipinary profes-
sionals (neurologists, geneticists, surgeons, genetic counsellors, thera-
pists and others) and family members with practical PKAN expertise. 
These experts drew on their direct experiences and trials and errors 
with PKAN to address key issues.  A detailed PubMed search was also 
utilised to identify and review all relevant published data. The team 
developed, drafted, and prepared a consensus guideline for publication. 
Results:  Management of PKAN patients is complex and needs to be 
tailored from diagnosis to end-stage disease. Our guideline addressed 
these relevant issues:
•	 Diagnostic evaluation
•	 Initial management (medical, genetic implications, psychosocial)
•	 Pharmacologic and surgical management





Conclusion:  A comprehensive document outlining the care and man-
agement of patients with PKAN benefits the entire NBIA community. 
This guideline not only serves to support new families as they are diag-
nosed, but also provides clear guidance to physicians and allied health-
care professionals. The experience we gain will inform the development 
of similar guidelines for other forms of NBIA.
Copyright: © 2014 Csányi et al.
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Overview of the NBIA Disorders - 
Neurodegeneration with Brain Iron Accumulation
S. J. Hayflick
Departments of Molecular & Medical Genetics, Pediatrics, and Neurology, Or-
egon Health & Science University, Portland, OR, USA
Neurodegeneration with brain iron accumulation comprises a clinically 
and genetically heterogeneous group of disorders. The NBIA disorders 
are recognizable by their clinical and radiographic features, which in-
clude changes arising from the accumulation of iron in the basal ganglia. 
As the genetic bases of these disorders have been identified, a unifying 
view of disease pathophysiology is becoming clear. While therapeutics 
for the NBIA disorders still focus on symptom management, the era of 
rational therapeutics to target the primary disease processes is within 
our view. This session will focus on the group of NBIA disorders, their 
clinical and MRI features, the genes and proteins that underlie them, 
and the diagnostic approach, which will highlight distinguishing fea-
tures of each of these disorders.
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Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-Univer-
sität, Munich, Germany
TIRCON (Treat Iron-Related Childhood-Onset Neurodegenera-
tion) is an international collaborative project funded by the European 
Commission´s Seventh Framework Programme and coordinated at the 
Ludwig-Maximilians-Universität of Munich, Germany. TIRCON aims 
at improving medical care, research infrastructure and therapeutic op-
tions for neurodegeneration with brain iron accumulation (NBIA), a 
group of rare hereditary neurodegenerative disorders characterized by 
high levels of brain iron. The most common form, accounting for ap-
proximately 50% of NBIA cases, is pantothenate kinase-associated neu-
rodegeneration (PKAN). Currently, there is no proven therapy to halt 
or reverse PKAN or any other form of NBIA. This is especially unfortu-
nate as both the iron accumulation in NBIA and the biochemical defect 
in PKAN are predicted to be amenable to drug-based treatment. 
TIRCON, for the first time, addresses this urgent and unmet need for 
a therapy for NBIA/PKAN by conducting a randomized placebo-con-
trolled clinical trial of the iron chelator deferiprone in PKAN (dura-
tion per patient 18 months). The four study sites in Munich (Germany), 
Oakland (USA), Milan (Italy) and Newcastle (UK) have (as of Novem-
ber 2014) already randomized more than 60 PKAN patients to this 
pivotal trial, approaching the planned number of 90 patients. Recruit-
ment will be completed until February 2015, and the last patient visit 
is therefore scheduled for August 2016. An extension trial, sponsored 
by the manufacturing company ApoPharma, has already started for the 
patients who completed the randomized trial. Regular meetings of the 
Data Safety Monitoring Board identified no major safety issues so far 
and unequivocally recommended continuation of the trial.
Another TIRCON work-package pursues essential preclinical work 
on pantethine and pantethine derivatives to treat PKAN. It has been 
shown in Drosophila that pantethine acts as an alternative precursor for 
CoA synthesis bypassing PANK2, the defective enzyme in PKAN, and 
leads to rescue of neurodegeneration and increase in life span. TIRCON 
is working on enhanced compounds and investigates their efficacy in 
mammalian models. This approach will lead to a firm conclusion of 
whether it is worthwhile to develop pantethine or pantethine-deriva-
tives into an established drug that could be used alone or in combina-
tion with deferiprone to treat PKAN.
The current lack of controlled clinical trials in NBIA is due to the rar-
ity and heterogeneity of these disorders and to previous fragmentation 
of research efforts. These limitations are most effectively overcome 
by an international patient registry. To this end, TIRCON has set up 
a harmonized international patient registry and biomaterial bank for 
all forms of NBIA to allow for natural history studies and biomarker 
development, two critical needs in the NBIA research community. As of 
November 2014, more than 100 NBIA patients have been enrolled pro-
spectively into the registry, and one-year follow-up data are currently 
available in 25 of them. In addition, retrospective data have been entered 
from more than 50 NBIA patients.
In conclusion, TIRCON has already succeeded in bringing together into 
one cohesive group the existing outstanding but scattered expertise in 
NBIA research and care at the European and international level. Medi-
cal care and research infrastructure have already noticeably improved, 
and the NBIA community is eagerly awaiting the outcome of the thera-
py research outlined above.
Copyright: © 2014 Klopstock
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Synthesis and Pharmacokinetic Properties of 
4-Thiobutyltriphenylphosphonium Pantetheine, a 
Novel Pantetheine Derivative
R. A. Lambrechts1, B. Srinivasan1, M. van der Zwaag1, E. M. 
Geertsema2, G. J. Poelarends2, M. de Villiers1,2, O. C. M. Sibon1
1 Department of Cell Biology, University Medical Center Groningen, Groningen, 
The Netherlands, 2 Department of Pharmaceutical Biology, University Medical 
Center Groningen, Groningen, The Netherlands
It has been shown that pantethine, the disulphide of pantetheine, rescues 
a Drosophila model of pantothenate kinase-associated neurodegenera-
tion (PKAN). However, the pharmacology of pantethine is known to 
be incompatible with its use as a possible replacement therapeutic for 
this neurodegenerative disease: the compound is known to be unstable 
in serum and is unlikely to permeate the blood-brain barrier. In an at-
tempt to overcome these pharmacological difficulties, we successfully 
synthesized 4-thiobutyltriphenylphosphonium pantetheine (TBTP-pan-
tetheine), a pantetheine derivative, and compared its serum stability and 
pharmacological properties to those of pantethine. 
It is shown that TBTP-pantetheine is stable under aqueous conditions; 
however, the compound is enzymatically degraded in fetal calf serum at 
a higher rate than its parent compound pantethine. In a PAMPA system 
(Parallel Artificial Membrane Permeability Assay, an in vitro setup to 
determine passive membrane transport), TBTP-pantetheine shows in-
creased lipophilicity by a significantly higher tendency to associate with 
the membrane; however, permeability coefficients are not significantly 
different. We conclude that TBTP-pantetheine is unable to overcome 
the pharmacological hurdles emerging from a pantethine-based thera-
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dystonia, pigmentary retinopathy,  
parkinsonism, acanthocytosis
T2 GP central hyperintensity 
with surrounding hypointensity – 
‘eye of tiger’ sign
psychomotor regression, dysto-
nia, parkinsonism, ataxia, optic 
atrophy
Cerebellar atrophy, GP and SN 
T2 hypointensity later childhood 
or adulthood
spasticity, dystonia, peripheral 
neuropathy, seizures
GP and SN T2 hypointensity
developmental disability, 
seizures, sleep problems, young-
onset parkinsonism
GP and SN T2 hypointensity; 
SN T1 hyperintense ‘halo’
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py for PKAN. Nevertheless, this research shows that pharmacological 
properties can be altered by derivatization of the parent molecule pan-
tethine thus strengthening the rationale to synthesize and test novel de-
rivatives of pantetheine and related molecules within TIRCON, in order 
to facilitate a possible replacement strategy in the future.
Copyright: © 2014 Lambrechts et al.
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Pantotenate Kinase-Associated Neurode-
generation: Clinical Assessment and Genetic 
Characterization by Means of a Spanish Multi-
Centre Research Network
B. Pérez-Dueñas1,7, A. Darling1, M. Serrano1,7, A. Decio1, D. Cua-
dras1, I. Gastón2, S. Aguilera2, M. Madruga3, P. Mir3, M. Pujol4, A. 
López5, L. Martorell1,7, C. Tello6, C. Espinós6,7, M. J. Martí8
1 Hospital Sant Joan de Déu, Barcelona, Spain, 2 Complejo Universitario de Na-
varra, Navarra, Spain, 3 Hospital Virgen del Rocio, Seville, Spain, 4 Hospital Santa 
Maria, Lleida, Spain, 5 ENACH Association (NBIA Spanish Association), Seville, 
Spain, 6 Centro de Investigación Príncipe Felipe, Valencia, Spain, 7 Centro de 
Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, 
Spain, 8 Hospital Clínic, Barcelona, Spain
Background: Pantothenate kinase associated neurodegeneration 
(PKAN) is the most common defect causing NBIA in children. Despite 
advances in the research of novel therapies for PKAN, validated inter-
national clinical rating scales to be used in clinical trials are lacking, 
and significant gaps concerning phenotype-genotype correlations and 
disease progression persist. 
Main Objective: We aimed to identify and genetically characterize the 
Spanish population with NBIA and to design and validate a quantitative 
method for clinical assessment of PKAN patients.  
Methodology: We performed a cross-sectional multi-centre study, with 
NBIA patient recruitment through professional associations. Design 
of a Disease Rating Scale for PKAN (PKAN-DRS) including four sub-
scales: cognitive, behavioral, physical, and functional assessment. Items 
were scored from 0 (normal) to 3 or 4 (maximum severity), (total scores 
0 (no disease) to 140 (maximum severity)). For validity and reliability 
assessment, four independent examiners rated PKAN patients using re-
corded videotapes. Sanger sequencing of NBIA genes was performed in 
undiagnosed NBIA families.
Results: To date, 37 NBIA patients (mean age 20 years, range 3-52; 13 
males) have been identified at 15 centres in Spain: PKAN (N=22); PLAN 
(N=8); undiagnosed NBIA (N=7). The PKAN-DRS was applied to 10 
PKAN patients (mean age 29, 5 years, range 14-53), total scores rang-
ing from 35 to 67. Physical scores positively correlated with functional 
scores, and age at disease onset inversely correlated with total scores. 
The c.1583C>T mutation in the PANK2 gene was found in homozygosis 
in 4 gypsy patients from two consanguineous families from Northern 
Spain, suggesting a common origin for this nucleotide change.
Copyright: © 2014 Pérez-Dueñas et al.
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Targeting Brain Iron in Neurodegenerative Disease
J. Connelly, C. J. Feeney, V. Rabadia, J. Xu, M. Premyslova, C. 
Peng, W. Yu, H. Xiong, L. Wang, T. Nitya-Nootan, M. Spino, J. 
Wodzinska
ApoPharma Inc., Toronto, Canada
Perturbation of iron homeostasis and accumulation of iron in specific 
regions of the brain play an important role in neurodegenerative pro-
cesses in all forms of NBIA, Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD), amyotrophic lateral sclerosis (ALS) and others. Iron deposi-
tion, whether a primary or secondary pathological event, may underlie 
or contribute to progression of neurodegeneration by promoting gen-
eration of reactive oxygen species (ROS), leading to oxidative cell dam-
age and brain inflammation.
ApoPharma’s marketed iron chelator, deferiprone, is a brain-permeable 
3,4-hydroxypyridinone (HP) with favourable activity in multiple ani-
mal models of neurodegenerative disease. Deferiprone has recently been 
shown to be effective in clinical trials in PD, and is being studied in 
pantothenate kinase-associated neurodegeneration (PKAN) and ALS 
patients. We have now developed a series of new HP iron chelators with 
improved properties. Model HPs penetrate the blood-brain barrier, cells 
and subcellular organelles, and selectively chelate Fe(III) with an affinity 
that facilitates transfer of iron to endogenous acceptors for reuse, avoid-
ing significant systemic iron depletion.
Using cellular and animal models of neurological cell protection, PD 
and AD, and an ataxic ceruloplasmin-hephestin double knockout (DKO) 
mouse, we have demonstrated the efficacy of selected HPs in alleviating 
brain iron deposition, neuroinflammation, and ROS-related cellular 
damage. Significant effects on disease-related endpoints included im-
provement of cognitive function in mouse AD and motor function in rat 
PD models, and prevention of ataxia in the DKO mouse. These findings 
may be generalized to other neurodegenerative disorders in which brain 
iron accumulation leads or contributes to disease pathology.
Copyright: © 2014 Connelly et al.
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Mitochondrial Dysfunction in Neurodegeneration 
with Brain Iron Accumulation (NBIA)
J. A. Sánchez-Alcázar1, M. Oropesa-Ávila1, J. Garrido-Maraver1, 
M. D. Cordero2,  M. de la Mata1, M. Villanueva Paz1, A. Delgado 
Pavón1, E. Alcocer-Gómez1, I. de Lavera1, R. Lema1, D. Cotán1
1 CABD-CSIC-Universidad Pablo de Olavide, Seville, Spain, 2 Facultad de Odon-
tología, Universidad de Sevilla, Seville, Spain
Pantothenate kinase 2 catalyzes the key, rate-limiting step in coenzyme 
A biosynthesis, therefore mutations in the gene encoding this enzyme 
have the potential to disrupt a number of metabolic processes by dis-
rupting cellular CoA pools. Elevations in lactate suggest that mutations 
in this mitochondrial enzyme could cause general mitochondrial dys-
function.
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services
8Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
doi: 10.7916/D8W957X3 NA/NBIA 2014 Abstracts: NBIA – Pantothenate Kinase-Associated Neurodegeneration
Particularly relevant for neurodegenerative processes is the relationship 
between mitochondria and iron. The mitochondrion upholds the syn-
thesis of iron–sulfur clusters and heme, therefore a fraction of incoming 
iron must go through this organelle before reaching its final destina-
tion. In turn, the mitochondrial respiratory chain is the source of reac-
tive oxygen species (ROS) derived from leaks in the electron transport 
chain. The co-existence of both iron and ROS in the secluded space of 
the mitochondrion makes this organelle particularly prone to hydroxyl 
radical-mediated damage. Additionally, mitochondrial dysfunction and 
ROS production promotes the selective degradation of damaged mi-
tochondria by autophagy which must be associated to increased mito-
chondrial biogenesis for compensating the loss of mitochondrial mass. 
Our project aims to understand the molecular mechanism and modula-
tion of mitophagy and mitochondrial biogenesis in cellular models of 
NBIA. 
1) Characterization of iron metabolism alterations, mitochondrial dys-
function and the molecular mechanisms involved in mitophagy activa-
tion in fibroblasts harbouring PANK2 mutations.
2) Molecular analysis of pathways involved in mitochondrial biogenesis 
as a compensatory mechanism in response to mitophagy activation in 
fibroblasts harbouring PANK2 mutations.
3) Screening of modulators of autophagy and mitochondrial biogenesis 
from commercial libraries capable of restoring the physiopathological 
alterations in PANK2 mutant fibroblasts.
Copyright: © 2014 Sánchez-Alcázar et al.
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Expression and Functional Analysis of the Zebrafish 
Pank2 Gene: A Possible Approach for the Study of 
PKAN, a Human NBIA
C. Saraceno, A. Guglielmi, D. Zizioli, R. Giuliani, G.  Borsani, E. 
Monti, P. Arosio, D. Finazzi
Department of Molecular and Translational Medicine, University of Brescia, 
Brescia, Italy
PKAN is the most common form of Neurodegeneration with Brain 
Iron Accumulation (NBIA); it is associated with mutations in the Pank2 
gene, coding for the rate limiting enzyme in CoA biosynthesis. We 
started to explore Pank2 biological function in Danio rerio, an excel-
lent vertebrate system to study developmental biology, gene function 
and to model human diseases. A bioinformatic analysis revealed the 
presence of a single pank2 gene on chromosome 13, with three differ-
ent transcripts. The longest one encodes for a putative protein of 437 
aminoacids with a good homology (65%) to the human counterpart. A 
reciprocal BLAST approach supports the hypothesis that the gene rep-
resents the Danio rerio ortholog of hPank2. This is further confirmed 
by the presence of synteny between the chromosomal regions in the two 
species. Contrary to the human ortholog that resides in the mitochon-
dria, the zebrafish protein shows prevalent localization in the cytosol 
when expressed in mammalian cells. qRT-PCR analysis revealed that 
the gene is expressed in all developmental stages, including the earliest 
ones, while in the adult organs it is highly represented in brain. The in 
situ hybridization technique confirmed the qRT-PCR  results, showing 
high expression in different brain structures and also in the vascular 
system. Preliminary results, obtained by the microinjection of a specific 
splicing-morpholino, revealed the presence of severe perturbation in the 
development of the nervous and vascular system at 24 and 48 hpf. The 
animal model could provide relevant information about the function of 
Pank2 and the mechanisms underpinning PKAN.
Copyright: © 2014 Saraceno et al.
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Neurodegeneration with Brain Iron Accumulation 
(NBIA): Insights from Gene Co-Expression 
Networks
C. Bettencourt1, M. Ryten1,2, S. Wiethoff1, P. Forabosco3, UK-
BEC, J. Hardy1, H. Houlden2
1 Department of Molecular Neuroscience, UCL Institute of Neurology, London, 
UK, 2 Department of Medical and Molecular Genetics, King’s College London, 
London, UK, 3 Istituto di Ricerca Genetica e Biomedica CNR, Cagliari, Italy
Neurodegeneration with brain iron accumulation (NBIA) constitutes a 
group of neurodegenerative diseases characterized by a prominent extra-
pyramidal movement disorder, intellectual deterioration and character-
istic iron deposition in the basal ganglia. Ten genes have been identified 
so far, but limited information exists regarding expression and function 
of these genes within the human brain.
To address possible relationships between known NBIA genes, predict 
their functions, and identify overlapping pathways, we used a systems-
biology approach based on whole transcriptome gene expression analy-
sis. As part of the UK Human Brain Expression Consortium (UKBEC), 
we analysed the expression profiles of 101 neuropathologically normal 
individuals (10 brain regions each). Weighted gene co-expression net-
work analysis (WGCNA) was used to cluster genes into co-expression 
modules. The overrepresentation of NBIA transcripts in basal ganglia 
modules (substantia nigra and putamen studied) was assessed.
Six modules containing NBIA genes were found for the substantia nigra, 
but there was no evidence of significant overrepresentation. Two puta-
men modules were significantly enriched for NBIA transcripts, namely 
the brown (PANK2, ATP13A2, C19orf12, COASY; P= 0.003) and green 
(FTL, DCAF17, FA2H; P= 0.021) modules. Enrichment analysis of these 
two putamen modules revealed an overrepresentation of gene ontology 
terms and KEGG pathways, including: brown - synaptic vesicle endo-
cytosis and axon cargo transport (biological processes), synaptic mem-
brane (cellular component), and synaptic vesicle cycle KEGG pathway; 
green - ensheathment of neurons, neuronal action potential and oligo-
dendrocyte development (biological processes), myelin sheath (cellular 
component), and cadherin binding (molecular function). Our data sug-
gests shared processes and pathways in NBIA gene networks.
Copyright: © 2014 Bettencourt et al.
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NBIA Alliance
H. Jaskolka1, A. Klucken1, N. Ali2, A. Lopez3, G. A. Marino4, A. 
Nagel5, N. Scalise6, M. Sheppard-Whalen7, M. van Schijndel5, J.-
L. Vasseur8, P. Wood9
1 Hoffnungsbaum e.V., Germany, 2 NBIA UK, UK, 3 ENACH Asociación, Spain,  
4 Buenos Aires, Argentina, 5 Stichting IJzersterk, The Netherlands, 6 AISNAF, Italy, 
7 CNBIA Canada, Canada, 8 AIDNAI, France, 8 NBIA Disorders Association, USA
The NBIA Alliance is the informal international umbrella organization 
for NBIA lay advocacy groups. Launched in 2012 under the patronage of 
the European Union Seventh Framework Programme (FP7 EU) project 
TIRCON (Treat Iron-Related Childhood-Onset Neurodegeneration), 
the NBIA Alliance’s main objectives are to increase awareness of NBIA 
and to support cooperative research into NBIA Disorders. As an inter-
face and contact point for all people in public and health policy with a 
special interest in NBIA, the NBIA Alliance and its members are bring-
ing together patients, clinicians, researchers, and further stakeholders. 
The NBIA Alliance comprises 6 legal entities in France, Germany, Italy, 
the Netherlands, Spain, and the United States, and one patient group 
still under development in the United Kingdom. New NBIA advocacy 
groups are just emerging in Argentina and Canada. 
The long-standing groups, Hoffnungsbaum e.V. in Germany and the 
NBIA Disorders Association in the U.S., are partners in TIRCON and 
have been fostering the establishment of further national NBIA lay ad-
vocacy groups and of the international NBIA Alliance. Herein these ad-
vocacy groups that are lesser-known to the international NBIA commu-
nity introduce themselves and describe their impact on NBIA research. 
AISNAF (Associazione Italiana Sindromi Neurodegenerative da Ac-
cumulo di Ferro) was established in 2006 as the third NBIA patient 
organization. It is a contact point for NBIA families in Italy, has raised 
awareness on NBIA and co-funded scientific symposia as well as NBIA 
research projects. It aims to help harmonize and spread clinical best 
practices in Italy. 
The French AIDNAI (Association Internationale de Dystrophie Neuro 
Axonale Infantile), launched in 2000 as a patient organization for NBIA 
subtype PLAN, supported research in PLAN, and extended its scope to 
all NBIA Disorders when becoming member of the NBIA Alliance in 
2012.
Inspired by an NBIA Alliance meeting at the 2nd joint NA/NBIA sym-
posium in Ede (the Netherlands) in October 2012, the Dutch Stichting 
IJzersterk was established in 2013. Using social media as an additional 
platform resulted in contact with 10 patient families within a year and 
fostered successful fundraisers for NBIA research.  
The establishment of the Spanish ENACH Asociación (Asociación de 
Enfermedades Neurodegenerativas por Acumulación Cerebral de Hi-
erro) in 2013, following the set-up of the NBIA Alliance, is focused on 
gaining visibility and extensive networking among NBIA families, re-
searchers and physicians. A  Scientific and Medical Advisory Board is 
already in place. Identifying a large patient cohort in Spain, the involve-
ment of 15 hospitals, setting up a research infrastructure and 4 ongoing 
research projects have been achieved within less than 2 years.
Additionally, NBIA UK, NBIA Canada and an Argentinian patient rep-
resentative have taken their first steps to setup organizations or to join 
the NBIA community.
Copyright: © 2014 Jaskolka et al.
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The Launch of the International Umbrella 
Organization NBIA Alliance in Relation to the 
EU-Funded FP7 Project TIRCON
A. Klucken1, H. Jaskolka1, P. Wood2, N. Ali3, A. Lopez4, A. Na-
gel5, F. Scalise6, N. Scalise6, M. Van Schijndel5, J.-L. Vasseur7, F. 
Gauzy-Krieger8, S. Hayflick9, T. Klopstock10
1 Hoffnungsbaum e.V., Velbert, Germany, 2 NBIA Disorders Association, USA, 3 
NBIA UK, UK, 4 ENACH Asociación, Spain, 5 Stichting IJzersterk, The Nether-
lands,  6 AISNAF, Italy,  7 AIDNAI, France, 8 Geschwister-Scholl-Institut für Politik-
wissenschaft, Ludwig-Maximilians-Universität, Munich, Germany, 9 Departments 
of Molecular & Medical Genetics, Pediatrics, Neurology, Oregon Health & Sci-
ence University, Portland, OR, USA, 10 Friedrich-Baur-Institute, Department of 
Neurology, Ludwig-Maximilians-Universität, Munich, Germany
Neurodegeneration with Brain Iron Accumulation (NBIA) is a group of 
ultra-rare neurological movement disorders characterized by high iron 
levels in the basal ganglia and a progressive degeneration of the nervous 
system. Currently, there is no cure or proven therapy for any of the 
NBIA forms.
Due to the lack of treatment options, the international European Union 
Seventh Framework Programme (FP7 EU) consortium TIRCON (Treat-
Iron-Related-Childhood-Onset-Neurodegeneration) is dedicated to the 
investigation of NBIA. 13 partners from eight countries are conducting 
a clinical therapy study and set up a patient registry/ biobank in order 
to improve the infrastructure for NBIA research and care.
The lay advocacy groups, NBIA Disorders Association (NBIADA, 
USA) and Hoffnungsbaum e.V. (HoBa, Germany), are full partners in 
TIRCON. Based upon their experience in such collaborative projects, 
NBIADA and HoBa have been promoting the creation of further patient 
groups worldwide. The NBIA Alliance, launched during the TIRCON 
kickoff meeting in 2012, is the first informal international umbrella as-
sociation for NBIA lay advocacy groups. Currently, seven NBIA pa-
tient organizations are involved in the Alliance. Its main objectives are 
to increase awareness for NBIA among the health care community by 
translating scientific knowledge into patient-friendly information and 
to support cooperative research. The NBIA Alliance is an information 
platform and a contact point for patients and clinicians where dedicated 
structures are not yet in place. The poster presents the launch, develop-
ment, goals, activities, constraints and future options of the NBIA Alli-
ance. It will underline the mutual empowerment of the NBIA patients’ 
movement and the NBIA research and care community in TIRCON.
Copyright: © 2014 Klucken et al.
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Exploring Novel Therapeutic Strategies for 
PLA2G6-Associated Neurodegeneration (PLAN)
M. A. Kurian1,2
1 UCL Institute of Child Health, London, UK 2 Great Ormond Street Hospital, 
London, UK 
Neurodegeneration with brain iron accumulation (NBIA) comprises a 
heterogeneous group of disorders with radiologically discernible brain 
iron. Phospholipase-associated neurodegeneration (PLAN) is the second 
most common subtype, accounting overall for 20% patients with NBIA. 
Three clinical subtypes are recognised, including classical infantile neu-
roaxonal dystrophy (INAD), atypical neuroaxonal dystrophy (NAD) 
and PLA2G6-related dystonia-parkinsonism.
It is well recognized that PLAN is a devastating condition with an ag-
gressive and relentless disease course. Children with INAD have pro-
gressive cognitive and motor difficulties, culminating in significant 
morbidity and reduced life expectancy. Currently, there are no disease-
modifying agents to halt the progression of this disorder, let alone a 
cure, and therefore all available treatments for PLAN currently focus on 
symptom palliation to maximize quality of life. 
At Great Ormond Street Hospital, we provide a tertiary service for 
many children with PLAN. I will discuss our current rationale for treat-
ment strategies in PLAN, namely the management of spasticity, dysto-
nia and secondary complications. I will also present data regarding the 
first reported use of deep brain stimulation in atypical NAD.
The paucity of disease-ameliorating treatments in PLAN has driven us 
to seek novel therapeutic strategies, and to that aim, we are currently 
undertaking a proof-of-concept gene therapy study in the INAD mouse 
model. This murine model recapitulates many of the clinical and his-
topathological features of the human phenotype, thereby rendering the 
model ideal for our study project. We will perform systemic intravenous 
delivery of an AAV9 viral vector to deliver therapeutic PLA2G6 gene 
to the INAD mouse model with the aim of rescuing and/or preventing 
neurodegenerative symptoms. Our ultimate long-term aim is to trans-
late this work to clinical trials for our patients with INAD and other 
forms of PLAN.
Copyright: © 2014 Kurian
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The UK Genotypic and Phenotypic Spectrum of 
Childhood Neurodegeneneration with Brain Iron 
Accumulation
E. Meyer1, B. Csanyi2, H. Houlden1, E. Kara1, J. Hardy1, M.A. Ku-
rian2,3
1 Department of Molecular Neuroscience, UCL Institute of Neurology, London, 
UK, 2 CMGU, Institute of Child Health, London, UK 3 Great Ormond Street 
Hospital, London, UK
Background: Neurodegeneration with brain iron accumulation (NBIA) 
comprises a clinically and genetically heterogeneous group of progres-
sive disorders characterised by high brain iron. Different genetic forms 
of NBIA encountered in childhood and early adolescence have been 
reported including pantothenate kinase-associated neurodegeneration 
(PKAN), PLA2G6-associated neurodegeneration (PLAN), mitochon-
drial membrane protein-associated neurodegeneration (MPAN), fatty 
acid hydroxylase-associated neurodegeneration (FAHN), beta-propeller 
protein-associated neurodegeneration (BPAN) and COASY protein-
associated neurodegeneration (CoPAN). To further define this group of 
disorders, we describe the clinical phenotypes and associated genotypes 
in our cohort of UK childhood-onset NBIA patients.
Methods: We undertook (i) clinical assessment and/or detailed analysis 
of the clinical notes and (ii) mutational analysis for relevant candidate 
genes.
Results: We studied 37 childhood-onset cases (5 familial and 26 spo-
radic) and confirmed a genetic diagnosis of NBIA in 19 (51.4%) patients 
(3 PKAN, 6 PLAN, 1 MPAN, 6 BPAN, 3 patients with a novel unpub-
lished gene defect). Beside the classical progressive motor symptoms and 
cognitive regression, many patients had additional extrapyramidal fea-
tures, ocular findings and neuropsychiatric features. We also identified 
unusual/rare clinical features in classical disease (e.g. absent eye-of-the-
tiger sign in PKAN) and a number of atypical disease presentations (e.g. 
atypical PLAN, early recognition of BPAN in infancy).
Conclusion: This review highlights that NBIA is both clinically and ge-
netically heterogeneous, and for many cases in the UK the genetic aetiol-
ogy is yet to be discovered. Further gene identification will significantly 
improve the understanding of disease mechanisms as well as identifying 
novel therapeutic targets for these neurodegenerative disorders.
Copyright: © 2014 Meyer et al.
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Decreased Brain Transcription of a Subset of 
NBIA-Related Genes with Possible Roles in Myelin 
Insights from an Hfe-/-Xtfr2mut Mouse Model of 
Brain Iron Loading
M. Heidari1, D. Johnstone1,2, B. Bassett1, R. Graham3,4, M.  Cum-
mins1, J. Olynyk3,5, D. Trinder3, R. Delima3 , A. Chua3, M. House6, 
E. Milward1
1 School of Biomedical Sciences and Pharmacy, University of Newcastle, New-
castle, NSW, Australia, 2 Bosch Institute and Discipline of Physiology, Univer-
sity of Sydney, Sydney, NSW, Australia, 3 School of Medicine and Pharmacology, 
University of Western Australia, Crawley, WA, Australia, 4 School of Biomedical 
Sciences, Curtin University of Technology, Curtin, WA, Australia, 5 Department 
of Gastroenterology, Fremantle Hospital, Fremantle, WA, Australia, 6 School of 
Physics, University of Western Australia, Crawley, WA, Australia
We have studied brain iron loading and related changes in a mouse 
model with mutations in the iron-regulatory genes Hfe and transferrin 
receptor 2 (Tfr2) and without known mutations in NBIA-related genes.
Brain iron and ferritin levels were increased (>1.7-fold, p<0.025, n≥5 
mice/group) and iron distribution altered in male Hfe-/-xTfr2mut AKR 
mice at 12 weeks of age after 3 weeks on a high iron diet (2% carbonyl 
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iron) compared to age- and gender-matched controls. Methods used 
included inductively coupled-atomic emission spectroscopy, non-heme 
iron assay, ferritin immunoblotting, micro X-ray fluorescence mapping 
of metal distribution and micro X-ray absorption near edge spectros-
copy analysis of iron species.
Brain RNA arrays revealed transcript decreases (p<0.05) for five NBIA-
related genes: phospholipase A2, group VI (PLA2G6, 1.7-fold), fatty acid 
2-hydroxylase (Fa2h, 1.4-fold), chromosome 19 open reading frame 12 
(C19orf12, 1.3-fold), ATPase13A2 (1.2-fold) and ceruloplasmin (Cp, 1.2-
fold). Four other NBIA-related transcripts for pantothenate kinase 2 
(PANK2) and CoA synthase (COASY), both involved in CoA metabo-
lism, WD-repeat domain 45 (implicated in autophagy) and the nuclear 
transmembrane protein DCAF17 were unchanged. Aside from the fer-
roxidase Cp, transcripts showing changes are distinguished by having 
myelin-related roles. At least 6 other myelin-related transcripts also de-
creased (p<0.05; ≥1.2-fold). 
These findings provide evidence that excess iron loading can cause de-
creases in the expression of a subset of the genes implicated in NBIA, 
notably those genes which may also have roles pertaining to myelin. 
Iron excess may therefore cause changes which resemble, although to a 
lesser degree, the effects of pathogenic, loss-of-function, NBIA-causing 
mutations in these genes.
Copyright: © 2014 Heidari et al.
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Resolution of an Undefined Case of NBIA with 
Miseq Technology
C. Panteghini, A. Legati, F. Invernizzi, L. Valletta, C. Barzaghi, 
C.Reale, B. Garavaglia
Molecular Neurogenetics Unit, Fondazione IRCCS Istituto Neurologico Carlo 
Besta, Milan, Italy
Neurodegeneration with brain iron accumulation (NBIA) includes a 
clinically and genetically heterogeneous group of disorders with progres-
sive extrapyramidal signs and neurological deterioration, characterized 
by iron accumulation in the basal ganglia. In our biobank, which is part 
of the Telethon Biobank Network, a considerable number of clinically 
associated NBIA cases without a genetic diagnosis are stored. In order 
to characterize this group we are studying our cohort of patients by the 
TruSeq Custom Amplicon panel (MiSeq Illumina platform) formed by 
16 NBIA-associated genes. We screened, using Sanger sequencing, one 
of three affected sisters for the most commonly NBIA-associated genes, 
identifying a heterozygous mutation in PANK2 (p.Gly521Arg), that was 
shared by the other two sisters. MLPA analysis ruled out exon rear-
rangements on the other allele. In order to extend the genetic screening, 
we sequenced the NBIA panel for one of these two sisters, discovering 
an additional mutation in PANK2 (p.Val517Met), that was absent in the 
first sister analyzed but present in the third sister.
Reviewing the sisters’ clinical history we observed differences between 
one sister and the other two with respect to age of onset and type of 
symptoms, differences that segregated appropriately  with the different 
genetic findings in PANK2. 
The sister carrying only the p. Gly521Arg is likely to be affected by a 
different disease and show a different phenotype due to the combined 
effect of the mutation and unknown susceptibility factors. The sequenc-
ing of the NBIA panel for this sister could be a powerful approach to 
complete the molecular diagnosis.
Copyright: © 2014 Panteghini et al.
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Iron Metabolism in the Central Nervous System 
and Implications for Human Disease
T. Rouault
National Institutes of Health, Bethesda, MD, USA
Abnormal accumulation of brain iron has been detected in various neu-
rodegenerative diseases, but the contribution of iron overload to pa-
thology remains unclear. In a group of distinctive brain iron overload 
diseases known as Neurodegeneration with Brain Iron Accumulation 
(NBIA), nine disease genes have been identified. In the NBIAs, brain 
iron accumulation was observed with MRI and at autopsy in the globus 
pallidus and other brain regions in patients and was associated with 
severe dystonia and gait abnormalites. Only two of these diseases, ac-
eruloplasminemia and neuroferritinopathy, are directly caused by ab-
normalities in iron metabolism, which affect mainly astrocytes in the 
former and neurons in the latter. Understanding the early molecular 
pathophysiology of these diseases should provide insights into the role 
of iron and to the design of specific therapeutic approaches.
Copyright: © 2014 Rouault
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Drosophila as a Tool to Identify Treatment 
Options for Pantothenate Kinase-Associated 
Neurodegeneration
O. C. M. Sibon 
Department of Cell Biology, University of Groningen, Groningen, The Nether-
lands
Pantothenate kinase-associated neurodegeneration (PKAN) is a rare 
inherited disease characterized by progressive movement impairment 
and iron accumulation in specific areas of the brain. Currently there are 
no treatment options for this devastating autosomal recessive disorder. 
Affected individuals carry mutations in pantothenate kinase, the first 
enzyme required to synthesize Coenzyme A, suggesting that impaired 
metabolism of Coenzyme A is one of the causes of the disease. This is 
further underscored by the recent finding that patients with mutations 
in Coenzyme A synthase, the last enzyme of the Coenzyme A biosyn-
thesis pathway suffer from comparable symptoms as PKAN patients. 
Coenzyme A is an essential metabolic cofactor required for over 100 
metabolic reactions. Why mutations in genes coding for Coenzyme A 
biosynthesis enzymes induce neurodegeneration is currently not clear. 
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We and others have investigated Drosophila neurodegenerative dPANK/
fumble mutants and demonstrated that these mutants can be used to 
understand basic mechanisms behind PKAN and to identify rescuing 
compounds which can be further explored for their use as possible treat-
ment options. We have identified various promising rescuing molecules 
able to rescue the observed abnormalities in dPANK/fumble mutants. 
Embedded within an international multidisciplinary consortium (TIR-
CON) we are aiming to understand the rescue potential of the com-
pounds. The valuable contribution of Drosophila to develop possible 
therapies for PKAN will be discussed.
Copyright: © 2014 Sibon
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VPS13C Mutations Associate with Frontotemporal 
lobar Degeneration and Decreased Protein 
Expression
M. Cruts1,2, S. Philtjens1,2, I. Gijselinck1,2, S.Van Mossevelde1,2, J. 
van der Zee1,2, T. Van Langenhove1,2, S. Engelborghs2,3, M. Van-
denbulcke4 , R. Vandenberghe5, P.Santens6, P. De Deyn2,3, C. Van 
Broeckhoven1,2
1 Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, 
VIB, Antwerp, Belgium, 2 Institute Born-Bunge, University of Antwerp, Antwerp, 
Belgium, 3 Department of Neurology and Memory Clinic, Hospital Network 
Antwerp, Middelheim and Hoge Beuken, Antwerp, Belgium, 4 Brain and Emotion 
Laboratory Leuven, Department of Psychiatry, University of Leuven and Univer-
sity Hospitals Leuven Gasthuisberg, Leuven, Belgium, 5 Laboratory for Cogni-
tive Neurology, Department of Neurology, University of Leuven and University 
Hospitals Leuven Gasthuisberg, Leuven, Belgium, 6 Department of Neurology, 
University Hospital Ghent and University of Ghent, Ghent, Belgium
Frontotemporal lobar degeneration (FTLD) represents a group of neu-
rodegenerative dementias mainly affecting people younger than 65 years 
of age. Up to 50% of patients have a family history of dementia and in 
most cases familial segregation is compatible with autosomal dominant 
inheritance. Although mutations in seven genes have been identified, 
the genetic cause remains unknown in about 60% of familial FTLD. We 
aimed to find novel FTLD genes in a whole genome sequencing ap-
proach in 13 unrelated familial patients and three relatives affected with 
FTLD, selected from a Belgian cohort of 590 FTLD patients. The ge-
nome sequences were annotated using GenomeComb and variants were 
filtered and prioritized using multiple genetic and functional criteria. 
Analysis of selected variants in all FTLD patients and 1314 matched 
controls revealed the presence of two novel coding missense variants 
(p.W395C and p.A444P) in the vacuolar protein sorting 13 homolog C 
gene (VPS13C). Further screening of the 86 coding exons of VPS13C 
in the Belgian FTLD cohort resulted in the identification of 18 addi-
tional mutations that were absent in the control group. The overall mu-
tation frequency was 4.1% (24 of 590 patients). Immunocytochemistry 
of lymphoblast cells of five patients with a VPS13C mutation suggested 
a 44-80% decreased expression (p<0.001) of VPS13C protein compared 
to mutation-negative controls (n=4), while mRNA expression was not 
altered. Extended genetic, neuropathological and cell biological studies 
are needed to support the role of VPS13C in FTLD.
Copyright: © 2014 Cruts et al.
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Approaching Our Goals Over Two Decades: 
A Summary of the 7th Neuroacanthocytosis 
Symposium
A. Danek
Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, 
Germany
From their start in 2002, and until very recently, the international neu-
roacanthocytosis (NA) symposia reported little tangible progress with 
respect to understanding the specific disease mechanisms that we antici-
pate will eventually form the basis of causal treatment. Our association 
with colleagues from the neurodegeneration with brain iron accumu-
lation (NBIA) field was not only a strategic alliance within the rare 
disease field but also a stimulus to speed the pace of discovery, 20 and 
13 years, respectively, after the discovery of the genes for McLeod syn-
drome (MLS: XK, encoding for Xk, identified in 1994) and chorea-acan-
thocytosis (ChAc VPS13A, encoding for chorein, identified in 2001). 
The small, close NA community, organized around the Advocacy for 
Neuroacanthocytosis Patients (www.naadvocacy.org), had been success-
ful in teaching our clinical colleagues about the NA syndromes, offer-
ing the free Western blot testing service to facilitate diagnosis of ChAc 
(instructions: www.euro-hd.net/html/na/diseases/chac), and providing 
information to fellow scientists. However, only with the European Mul-
tidisciplinary Initiative on Neuroacanthocytosis (EMINA) which ter-
minated in early 2014, and its currently active successor, EMINA-2, have 
new basic science discoveries come at a quicker pace. The most recent 
development is the very welcome interest by the European collabora-
tion program in science and technology (COST) and its “proteostasis 
action” (proteostasis-2014.cipf.es). 
The current NA symposium presented a number of potential ChAc 
models, in yeast, slime mould, drosophila, and human induced pluripo-
tent stem cells. New insights were presented into the roles of VPS13A 
and chorein, in particular a possible association with mitochondrial 
function. Important progress was also reported on VPS13B and VP-
S13C function, the first causing Cohen syndrome (a progressive disease 
only with respect to retinopathy), the latter linked to a frontotempo-
ral dementia syndrome. VPS13D still seems enigmatic. Little progress 
has been reported in MLS, which much rarer than ChAc. Huntington 
disease-like type 2 (HDL-2) was not covered at the current meeting. 
There has been great progress in the NBIA syndromes, especially in 
pantothenate kinase-associated neurodegeneration (PKAN), with the 
identification of new syndromes caused by novel genes, with significant 
progress in disease models, and with treatment being offered in the 
TIRCON project. Given the new genetic data and the well-organized 
patient cohorts with NBIA syndromes, the relationship of PKAN and 
the other syndromes to acanthocytosis may be further elucidated once 
blood smears and acanthocyte counts are systematically performed in 
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these subjects. These findings will also inform us about the future utility 
of NA and NBIA cooperation.
Copyright: © 2014 Danek
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Functional Studies of the Cohen Syndrome-
Associated Protein VPS13B (COH1)
W. Seifert1, J. Kühnisch2,3, T. Maritzen4, S. Lommatzsch1, H. C. 
Hennies5,6,7, S. Bachmann1, D. Horn2, V. Haucke4
1 Institute of Vegetative Anatomy, Charité - Universitätsmedizin Berlin, Berlin, 
Germany, 2 Institute for Medical and Human Genetics, Charité - Universitäts-
medizin Berlin, Berlin, Germany, 3 Max-Planck-Institute for Molecular Genetics, 
FG Development and Disease, Berlin, Berlin, Germany, 4 Department of Mo-
lecular Pharmacology and Cell Biology, Leibniz-Institute for Molecular Pharma-
cology, Berlin, Germany, 5 Cologne Center for Genomics (CCG), University of 
Cologne, Cologne, Germany, 6 Cologne Excellence Cluster on Cellular Stress 
Responses in Aging-Associated Diseases (CECAD), University of Cologne, Co-
logne, Germany, 7 Division of Human Genetics, Innsbruck Medical University, 
Innsbruck, Austria
Cohen syndrome is an autosomal recessive disorder caused by muta-
tions in the gene VPS13B (COH1). Prominent clinical features are in-
tellectual disability, postnatal microcephaly, pigmentary retinopathy, 
and intermittent neutropenia. However, the biochemical characteristics, 
cellular localization, or functional role of the encoded protein COH1 
remain largely unidentified. Our cell biological analysis showed local-
ization of COH1 to the Golgi complex. Further biochemical analysis 
demonstrated that COH1 is a peripheral membrane protein similar to 
its remote yeast homologue Vps13p. Vps13p regulates anterograde and 
retrograde vesicular transport of transmembrane proteins between the 
prevacuolar compartment and the trans-Golgi network. We found that 
loss of COH1 impairs the ability of the Golgi complex to (re)assemble 
and thus induces fragmentation into mini-stacks. Furthermore, COH1 
regulates the formation of Golgi-derived membrane tubules consistent 
with its likely function in intracellular trafficking. In summary, our 
study identifies COH1 as a Golgi matrix protein required for maintain-
ing Golgi integrity and function. Another study showed that disturbed 
Golgi complex homeostasis upon loss of COH1 causes major defects of 
glycan maturation. Experiments blocking secretion using Brefeldin A 
identified no major intracellular retrograde trafficking defects. How-
ever, COH1-deficient cells display a reduced amount of early endosomes 
and abnormally enlarged lysosomes, pointing to a role of COH1 in 
endosomal-lysosomal trafficking. Together, these results provide an im-
proved insight into the molecular function of COH1 in Golgi-associated 
intracellular trafficking, which in the future may help to unravel its role 
in brain development, neuronal function, and general pathology in pa-
tients with Cohen syndrome.
Copyright: © 2014 Seifert et al.
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Diagnosis and Treatment of Chorea and Dystonia
R. H. Walker1,2
1 Department of Neurology, James J Peters VAMC, Bronx, NY, USA, 2 Mount 
Sinai School of Medicine, New York, NY, USA
Chorea and dystonia are hyperkinetic movements which can be seen in a 
number of basal ganglia neurodegenerative disorders. These movements 
can often coexist - it is important to properly identify the phenomenol-
ogy as the underlying mechanisms are likely to be distinct, and differ-
ent therapies may be indicated.  Both types of involuntary movements 
can be caused by a large number of disorders, including pharmacologic, 
structural, metabolic, genetic and degenerative etiologies. Features of 
the history, including family history, medical history, disease onset, 
and progression, inform the diagnosis. These features guide diagnostic 
testing which often includes brain imaging, and laboratory testing for 
potentially reversible etiologies and informative biomarkers. New tech-
nologies are permitting us to identify causative genes in rare disorders 
and expanding the phenotype of known disorders.  Therapy for genetic 
diseases is in its infancy, and has not yet been successfully employed for 
diseases affecting the central nervous system. Despite this, it is essential 
to pursue the diagnosis in order to provide genetic counseling, guidance 
regarding future disease progression, and to expand our knowledge of 
rare neurodegenerative disorders. Current treatments are focused upon 
reducing symptoms and maintaining and optimizing function. This can 
be optimally accomplished using a multidisciplinary team approach. 
Pharmacologic and focal neurotoxin injections can help reduce involun-
tary movements, but are likely to be more effective in combination with 
other modalities, such as speech, occupational, and physical, therapies. 
Deep brain stimulation likely has some utility, but therapeutic goals 
and potential benefits should be clearly identified before performing an 
invasive procedure in progressive, neurodegenerative disorders.
Copyright: © 2014 Walker
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